TECHNETIUM TC99M MERTIATIDE KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TECHNETIUM TC99M MERTIATIDE KIT (TECHNETIUM TC99M MERTIATIDE KIT).
Technetium Tc99m mertiatide is a radiopharmaceutical that undergoes renal tubular secretion and glomerular filtration, allowing imaging of the kidneys. After intravenous administration, it is primarily taken up by the kidneys and excreted into the urine, providing visualization of renal perfusion and function.
| Metabolism | Technetium Tc99m mertiatide is primarily eliminated by the kidneys via glomerular filtration and tubular secretion. It does not undergo significant hepatic metabolism. |
| Excretion | Renal: >90% of injected dose excreted via glomerular filtration and tubular secretion within 24 hours. Biliary/fecal: <1%. |
| Half-life | Terminal elimination half-life: 1.5–2.1 hours (mean 1.8 h). Effective half-life with Tc-99m decay: physical half-life 6.02 h, biological half-life ~1.8 h, effective half-life ~1.4 h. Clinically, imaging completed within 30–60 min post-injection. |
| Protein binding | ~4% bound to plasma proteins (mainly albumin). |
| Volume of Distribution | 0.12–0.15 L/kg (approx. 8–10 L in a 70 kg adult); confined to extracellular fluid and renal parenchyma. |
| Bioavailability | Not applicable via oral route; only administered intravenously (bioavailability 100% by IV). |
| Onset of Action | Intravenous: Renal accumulation begins within 1 minute; peak renal activity at 3–5 minutes post-injection. |
| Duration of Action | Image acquisition optimal 10–60 minutes post-injection; adequate diagnostic signal for up to 4 hours. Renal excretion reduces background activity rapidly. |
1 mCi (37 MBq) intravenously as a single dose for renal imaging.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment required; drug excreted renally but used for renal function assessment. |
| Liver impairment | No dose adjustment needed; hepatic impairment does not alter pharmacokinetics. |
| Pediatric use | Weight-based: 0.1 mCi/kg (3.7 MBq/kg) minimum 1 mCi, maximum 5 mCi intravenously. |
| Geriatric use | No specific adjustment; use standard adult dose considering renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TECHNETIUM TC99M MERTIATIDE KIT (TECHNETIUM TC99M MERTIATIDE KIT).
| Breastfeeding | Tc-99m is excreted in breast milk with an M/P ratio of approximately 1.0. Interrupt breastfeeding for 24-48 hours post-administration; discard expressed milk during this period. |
| Teratogenic Risk | Fetal radiation exposure is dose-dependent. First trimester: highest risk of deterministic effects (e.g., growth restriction, CNS abnormalities) at >100 mGy. Second/third trimester: lower risk but possible carcinogenesis. The drug is contraindicated in pregnancy unless benefit outweighs risks. |
■ FDA Black Box Warning
Not available (no FDA black box warning for this drug).
| Serious Effects |
["Hypersensitivity to technetium Tc99m or any component of the kit.","Pregnancy (unless potential benefit outweighs risk); consider alternative imaging.","Lactation (discontinue breastfeeding or avoid use)."]
| Precautions | ["Risk of radiation exposure, particularly in pregnant women and children; use only when necessary.","Allergic reactions including anaphylaxis may occur; have resuscitation equipment available.","Technetium Tc99m mertiatide may accumulate in the bladder; encourage hydration to reduce radiation dose to bladder wall.","Not intended for therapeutic use; strictly diagnostic."] |
Loading safety data…
| Fetal Monitoring |
| Monitor fetal radiation exposure via dosimetry. Assess maternal renal function pre-dose as excretion is renal. No specific fetal monitoring required unless high dose. |
| Fertility Effects | No known direct fertility effects from Tc-99m meritatide. Radiation exposure to gonads may theoretically affect gametogenesis, but diagnostic doses are far below thresholds for clinically relevant impairment. |